Market Overview

BlueLinx Wins Distribution Agreement for Weyerhaeuser Engineered Wood Products in New England

Share:

BlueLinx Corporation today announced a new distribution agreement with Weyerhaeuser to become the independent distributor of Weyerhaeuser's engineered wood products, including Trus Joist® TJI® joist, TimberStrand® LSL, Microllam® LVL, Parallam® PSL, and TJ® Rim board, in the New England area effective today, February 13, 2012.

"We used a rigorous process to select our New England distributor," said Jeff Rettig, Weyerhaeuser Region Manager for the Northeast. "BlueLinx emerged as the best fit for this market based on its operational capabilities, alignment with our local strategy, and strong reputation and relationship with our current New England customer base."

"We're excited about the opportunity to work in New England with a reputable company like Weyerhaeuser," said Gregg Brummer, BlueLinx Vice President for the Northeast. "Weyerhaeuser has a long-standing presence in the forest products industry and distribution is an important part of their success. As we moved through the selection process it became clear that we share a lot in common, including a deep commitment to New England and taking care of our customers, which makes Weyerhaeuser and BlueLinx a great fit. We are looking forward to getting started."

Posted-In: News Contracts Global

 

Related Articles (BXC)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Duoyuan Global Water Announces Decision to Appeal NYSE Decision to Delist

Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes